Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Ketamine 0.25 mg/kg/Dose | A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks. Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant). | None | None | 0 | 2 | 0 | 2 | View |
| Ketamine 0.5 mg/kg/Dose | A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks. Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant). | None | None | 0 | 1 | 0 | 1 | View |
| Ketamine 1 mg/kg/Dose | A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks. Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant). | None | None | 0 | 0 | 0 | 0 | View |
| Placebo | Placebo | None | None | 0 | 1 | 0 | 1 | View |